Tema Oncology ETF (CANC)
NASDAQ: CANC
· Real-Time Price · USD
27.01
-0.35 (-1.29%)
At close: Sep 10, 2025, 3:49 PM
26.93
-0.28%
After-hours: Sep 10, 2025, 04:10 PM EDT
-1.29% (1D)
| Bid | 26.82 |
| Market Cap | 69.61M |
| AUM | 75.63M |
| NAV | 27.7 |
| EPS (ttm) | 1.06 |
| PE Ratio (ttm) | 25.43 |
| Shares Out | 2.58M |
| Inception Date | Aug 13, 2023 |
| Ask | 27.13 |
| Volume | 5,777 |
| Open | 27.37 |
| Previous Close | 27.36 |
| Day's Range | 26.88 - 27.37 |
| 52-Week Range | 20.10 - 29.81 |
| Holdings | 52 |
| Expense Ratio | 0.75% |
About CANC
The actively managed Tema Oncology ETF seeks to provide long-term growth by investing in companies operating in the oncology industry. Cancer is the second deadliest killer but is on the brink of a revolution in therapeutics and diagnosis.
Asset Class Equity
Ticker Symbol CANC
Inception Date Aug 13, 2023
Provider Other
Website Fund Home Page
Exchange NASDAQ
Top 10 Holdings 40.30% of assets
| Name | Symbol | Weight |
|---|---|---|
| Revolution Medicines... | RVMD | 5.85% |
| Eli Lilly And Compan... | LLY | 4.74% |
| Bridgebio Pharma, In... | BBIO | 4.71% |
| Genmab A/s | GMAB | 4.46% |
| Roche Holding Ag | RHHBY | 4.25% |
| Merus N.v. | MRUS | 3.83% |
| Beone Medicines Ltd. | ONC | 3.28% |
| Nuvalent, Inc. | NUVL | 3.20% |
| Arcellx, Inc. | ACLX | 3.06% |
| Bristol-myers Squibb... | BMY | 2.92% |
Dividends Dividend Yield 2.78%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Dec 11, 2024 | $0.7283 | Dec 12, 2024 |
| Dec 13, 2023 | $0.1491 | Dec 15, 2023 |
